Pomalidomide-PEG2-CO2H

Background Introduction

Pomalidomide-PEG2-CO2H is a versatile E3 ligase ligand-linker conjugate designed for use in the development of targeted protein degradation technologies, particularly PROTACs (Proteolysis Targeting Chimeras). By incorporating the immunomodulatory drug pomalidomide, which selectively recruits the cereblon E3 ubiquitin ligase, and a PEG2-CO2H linker, this compound provides an optimal scaffold for linking to various target protein ligands, streamlining the discovery and synthesis of highly effective PROTAC molecules.

Mechanism

The mechanism of action of Pomalidomide-PEG2-CO2H centers around its dual-functional design. The pomalidomide moiety serves as a high-affinity ligand for cereblon, a key E3 ubiquitin ligase in the ubiquitin-proteasome system. The PEG2-CO2H linker offers enhanced solubility and flexibility for conjugation. When incorporated into a PROTAC molecule, Pomalidomide-PEG2-CO2H brings the cereblon E3 ligase in close proximity to a protein of interest, which is tagged by an appropriate binding moiety on the opposite end of the linker. This promotes ubiquitination of the target protein and its subsequent degradation by the 26S proteasome, offering a highly specific mechanism for targeted protein knockdown.

Applications

Pomalidomide-PEG2-CO2H is widely used in the research and development of PROTACs and other targeted degradation modalities. Its primary applications include the synthesis of cereblon-recruiting PROTACs for chemical biology studies, target validation, and drug discovery in oncology, neurodegenerative diseases, and other therapeutic areas. By enabling selective degradation of undruggable or challenging targets, this E3 ligase ligand-linker conjugate accelerates the identification of lead compounds and expands the scope of precision medicine.